RNA Interference – Page 2

Alnylam Achieves Breakthrough in Heart Study with RNAi Therapy Vutrisiran

10 months ago talkbio0Tagged Alnylam, Amyloidosis, Cardiomyopathies, RNA Interference, TTR wt Allele, vutrisiran

Alnylam, Vutrisiran, RNAi Therapy, Heart Study, ATTR Amyloidosis, Cardiomyopathy

Roche and Alnylam’s Hypertension Hopeful Zilebesiran Shows Promising Results in Combination Therapy Trial

1 year ago talkbio0Tagged Alnylam, Angiotensinogen, Combined Modality Therapy, control of blood pressure, Hypertensive disease, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, RNA Interference, Roche (company), Safety, Zilebesiran

Roche, Alnylam, Zilebesiran, Hypertension, Combination Therapy, Phase 2 Trial, Blood Pressure Control, AngioTensinogen (AGT), RNA Interference (RNAi) Therapeutic, Significant Reductions in Systolic Blood Pressure, Encouraging Safety Profile

Second Positive Phase 2 Trial Boosts Confidence in Alnylam’s RNAi Blood Pressure Med, Supporting Roche’s $2.8 Billion Biobucks Bet

1 year ago talkbio0Tagged Alnylam, blood pressure medication, Hypertension therapy, KARDIA-2, milestone payments, Partnership, RNA Interference, Roche (company), Systolic blood pressure reduction, Zilebesiran

Alnylam RNAi blood pressure medication, Zilebesiran, Phase 2 trial success, Systolic blood pressure reduction, Roche partnership, $2.8 billion milestone payments, Hypertension therapy, KARDIA-2 study